Protagonist Therapeutics (PTGX) Profit After Tax (2015 - 2026)
Protagonist Therapeutics (PTGX) posted Profit After Tax of $3.8 million for Q1 2026, up 108.52% sequentially from -$44.4 million in Q4 2025, and up 132.46% YoY from $1.6 million in Q1 2025.
Protagonist Therapeutics (PTGX) Profit After Tax (2015 - 2026) Analysis & Trends
Protagonist Therapeutics has reported Profit After Tax for 12 years, with the latest figure at $3.8 million in Q1 2026.
- Quarterly Profit After Tax rose 132.46% year-over-year to $3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$114.7 million (down 304.14% YoY) and the FY2025 annual result came in at -$130.1 million, down 147.29% from the prior year.
- Profit After Tax improved to $3.8 million in Q1 2026 per PTGX's latest filing, from -$44.4 million in the prior quarter.
- Over five years, Profit After Tax peaked at $207.3 million in Q1 2024 and troughed at -$44.4 million in Q4 2025.
- A 5-year average of -$3.4 million and a median of -$33.2 million in 2024 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2024 and 2025: Profit After Tax soared 714.8% in 2024, then slumped 133.71% in 2025.
- Over 5 years, Profit After Tax stood at -$34.2 million in 2022, then surged by 179.94% to $27.3 million in 2023, then soared by 381.7% to $131.7 million in 2024, then plunged by 133.71% to -$44.4 million in 2025, then surged by 108.52% to $3.8 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered $3.8 million, -$44.4 million, and -$39.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Protagonist Therapeutics | 10.03 Bn | 10.03 Bn | - | 162.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 162.85 Mn |
| Mar 31, 2026 | 3.78 Mn |
| Dec 31, 2025 | -44.38 Mn |
| Sep 30, 2025 | -39.34 Mn |
| Jun 30, 2025 | -34.77 Mn |
| Mar 31, 2025 | -11.66 Mn |
| Dec 31, 2024 | 131.67 Mn |
| Sep 30, 2024 | -33.21 Mn |
| Jun 30, 2024 | -30.62 Mn |
| Mar 31, 2024 | 207.34 Mn |
| Dec 31, 2023 | 27.34 Mn |
| Sep 30, 2023 | -34.11 Mn |
| Jun 30, 2023 | -38.46 Mn |
| Mar 31, 2023 | -33.73 Mn |
| Dec 31, 2022 | -34.19 Mn |
| Sep 30, 2022 | -31.23 Mn |
| Jun 30, 2022 | -41.04 Mn |
| Mar 31, 2022 | -20.93 Mn |
| Dec 31, 2021 | -36.91 Mn |
| Sep 30, 2021 | -33.80 Mn |